4DMedical Limited (ASX:4DX) Signs Contract with Perth Radiological Clinic
Contract Details
4DMedical Limited (ASX: 4DX) has signed a significant contract with Perth Radiological Clinic (PRC) to deploy its XV Technology®-enabled ventilation reports across 16 clinics in Perth. This strategic partnership marks a vital milestone in 4DMedical’s expansion in the Australian healthcare market.
Partnership Significance
PRC is a prominent diagnostic imaging provider in Western Australia, servicing a large portion of the Perth population. The collaboration was accelerated following 4DMedical’s successful presentation at the RANZCR Annual Scientific Meeting, where the benefits of XV Technology® were showcased to PRC’s radiology team.
Product Delivery Model
The contract allows referring doctors to request both CT LVAS™ and XV LVAS® ventilation reports, provided via existing imaging infrastructure. Reports will be delivered through a Software-as-a-Service (SaaS) model, reinforcing 4DMedical’s innovative approach to respiratory diagnostics. The contract is effective until 30 September 2025.
CEO Comments
4DMedical CEO and Founder, Prof. Andreas Fouras, stated, “We are delighted to partner with PRC, a leader in diagnostic imaging in Western Australia. This collaboration underscores the value and demand for XV Technology® in enhancing respiratory diagnostics.” He expressed optimism about the company’s growth momentum, highlighting recent wins and forthcoming collaborations.
Future Outlook
This contract strengthens 4DMedical’s market presence while contributing to advancements in respiratory health diagnostics. The company will spotlight its innovations at the upcoming RSNA Annual Meeting, presenting a session focused on collaborations aimed at improving care access and outcomes for patients, especially veterans.
Company Background
4DMedical Limited is a global medical technology firm that delivers advanced lung function assessment solutions. Its flagship XV Technology® enables nuanced understanding of regional airflow, providing earlier identification of respiratory deficiencies. Following its recent acquisition of Imbio, the company aims to enhance patient care through artificial intelligence applications in medical imaging.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.